Pakistani pharmaceutical giant Ferozsons Laboratories Limited (FEROZ) has signed a non-exclusive, royalty-free licensing agreement with US-based Gilead Sciences to manufacture and distribute its investigational once-yearly Lenacapavir for HIV prevention across 120 high-incidence, low- and lower-middle-income countries.
Key Highlights:
- Technology Transfer: Gilead will transfer its proprietary manufacturing process to Ferozsons, enabling the company to scale up production of both oral and injectable formats.
- Manufacturing Division: Ferozsons will contract manufacture the injectable variant at its joint-venture subsidiary, BF Biosciences Limited (BFBIO), while manufacturing and selling the oral variant directly.
- Global Access: The agreement aims to prepare manufacturing readiness and future supply planning for 120 countries while Phase 3 clinical trials continue.
Investor Takeaway: This high-profile global alliance significantly enhances the operational profile and export pipeline for Ferozsons (FEROZ) and its recently listed JV subsidiary BF Biosciences (BFBIO), presenting a strong positive long-term growth catalyst.
Read the full story on the original publisher’s website.
Open original article